Voyager Therapeutics shifts focus for ALS therapy
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...
Voyager Therapeutics to Assess 'Alternative Payloads' for ALS Gene Therapy Program
Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.
ALS News Today23h
US trial of noninvasive ALS device gets green light to enroll patients
A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...
News Medical3d
Living in disadvantaged areas reduces ALS survival time by over 30%
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests.
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.
ALS survival may be cut short by living in disadvantaged communities
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, ...